enGene Holdings

ENGN

Market cap $540M

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has selected detalimogene voraplasmid (also known as detalimogene and previously EG-70) to participate in the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program. Detalimogene is a novel, investigational, non-viral gene therapy for patie.

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Alex Nichols, Ph.D., Chief Strategy and Operations Officer, will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 12:10 p.m. ET. A webcast of the presentation can be accessed on the "Events and Presentations” page under the “Investors” section of the enGene website at www.engene.com and wil.

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the pricing of its previously announced underwritten public offering of 12,558,823 common shares at a public offering price of $8.50 per share and pre-funded warrants to purchase 2,735,295 shares of its common shares at an offering price of $8.4999 per pre-funded warrant, in each case, before underwriting discounts and commiss.

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it has commenced an underwritten public offering of its common shares. All common shares to be sold in the offering will be offered by enGene. In addition, enGene intends to grant the underwriters a 30-day option to purchase up to a number of additional common shares equal to 15% of the total number of common shares sold.

enGene Holdings remains a Buy, driven by promising LEGEND trial data for detalimogene voraplasmid in non-muscle invasive bladder cancer. ENGN's phase 2 LEGEND trial showed a 63% complete response rate, comparable to ImmunityBio's Anktiva, positioning ENGN as a strong NMIBC contender. ENGN has a robust cash runway into 2027, supporting continued operations and potential approval without immediate fundraising concerns.

enGene Holdings Inc. ( ENGN ) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC November 11, 2025 8:00 AM EST Company Participants Lauren Hopfer Ronald H. Cooper - President, CEO & Director Hussein Sweiti - Chief Medical Officer Conference Call Participants Suzanne Merrill Yanan Zhu - Wells Fargo Securities, LLC, Research Division Judah Frommer - Morgan Stanley, Research Division Sean McCutcheon - Raymond James & Associates, Inc., Research Division Mani Foroohar - Leerink Partners LLC, Research Division Paul Jeng - Guggenheim Securities, LLC, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Andres Maldonado - H.C.

enGene Holdings Inc. (NASDAQ:ENGN) stock is edging higher on Tuesday, with a session volume of 18.62 million compared to an average volume of 266.85 thousand, as per data from Benzinga Pro.

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported additional preliminary data from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene and previously EG-70) in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ (CIS) with or without conco.

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a conference call and webcast tomorrow, November 11, 2025, at 8:00 a.m. ET to discuss new preliminary data from its pivotal cohort in the ongoing LEGEND trial of its novel, non-viral gene therapy candidate, detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with high-ri.

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation Conference Date: Tuesday, November 11, 2025 Time: 12:30 p.m. ET Stifel 2025 Healthcare Conference Date: Wednesday, November 12, 2025 Time: 2:00 p.m. ET Jefferies Global Healthcare Conference in London Date: Tuesday,.